Nuclear Medicine Unit
In 1980 Giovanni Paganelli received his degree in Medicine and Surgery at University of Bologna, Italy. In 1997 he optimized the lymphoscintigraphic technique for the detection of the sentinel node in breast cancer and conceived Radio-guided Occult Lesion Localization (ROLL), a new non-palpable lesions localization system. His main field of interest is the in vivo application of the avidin-biotin system and radiolabelled peptides. He is engaged in investigating new radiopharmaceuticals for targeted molecular radionuclide therapy in oncology and radiolabeled peptides in neuroendocrine tumors as well as new approach in their application for diagnostic and therapeutical purposes. Among other honors, Prof. Paganelli is the 1998 recipient of the Marie Curie Award from the European Association of Nuclear Medicine. He is the owner of several International Patents and has been an invited lecturer at several Italian and International Universities. From February 2001 to December 2003, he served as an Expert of the Consiglio Superiore di Sanità (Italian Health Commission). His Official H index it’s equal to 67.0 and he is Author/co-author of more than 360 articles in leading international peer-reviewed journals as well as he is member of the editorial board of several scientific Journals (e.g. EJNMMI, QJNMMI, Cancer Bioth & Rad, Clin.Trans.Imag. ).
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
European journal of nuclear medicine and molecular imaging Oct, 2014 | Pubmed ID: 24615468
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
European journal of nuclear medicine and molecular imaging Nov, 2015 | Pubmed ID: 26611427
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE.
European journal of nuclear medicine and molecular imaging Mar, 2017 | Pubmed ID: 27704193
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE.
European journal of nuclear medicine and molecular imaging 02, 2017 | Pubmed ID: 27807661
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.
European journal of nuclear medicine and molecular imaging 09, 2017 | Pubmed ID: 28331955
Reduction of Ga-PSMA renal uptake with mannitol infusion: preliminary results.
European journal of nuclear medicine and molecular imaging Dec, 2017 | Pubmed ID: 28801787
Investigation of receptor radionuclide therapy with Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.
European journal of nuclear medicine and molecular imaging 06, 2018 | Pubmed ID: 29387927
[Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?
The Lancet. Oncology 06, 2018 | Pubmed ID: 29752181
Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.
European journal of nuclear medicine and molecular imaging 11, 2018 | Pubmed ID: 29922948
Maria Luisa Belli1,
Emilio Mezzenga1,
Valentina Di Iorio2,
Monica Celli3,
Paola Caroli3,
Elisabeth Canali3,
Federica Matteucci3,
Elisa Tardelli3,
Ilaria Grassi3,
Maddalena Sansovini3,
Silvia Nicolini3,
Stefano Severi3,
Marta Cremonesi4,
Mahila Ferrari5,
Giovanni Paganelli3,
Anna Sarnelli1
1Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy,
2Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy,
3Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy,
4Radiation Research Unit, Istituto Europeo di Oncologia (IEO) IRCCS, Milano, Italy,
5Medical Physics Unit, Istituto Europeo di Oncologia (IEO) IRCCS, Milano, Italy
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。